Stereotaxis has submitted an application seeking CE mark for its robotically navigated MAGiC catheter.
The magnetic interventional ablation catheter has been designed for use in minimally invasive cardiac ablation procedures.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It has been developed to provide precision, stability and flexibility during the testing and treating of cardiac arrhythmias.
Developed in partnership with Osypka, a German medical device company, the catheter is used with Stereotaxis’s robotic systems.
Stereotaxis stated that the MAGiC catheter has many features that help to improve patient safety as well as efficacy, physician experience and procedural efficiency.
Stereotaxis chairman and CEO David Fischel said: “We are very pleased to reach this important milestone. This is a seminal event for Stereotaxis as a company and for the physician community that is pioneering the frontiers of robotics in electrophysiology.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Our attention is focused on preparing for commercial launch of the catheter once we receive regulatory clearance.
“We look forward to the positive impact MAGiC can have on patients, physicians, providers and medical progress.”
MAGiC serves as a platform for future innovations and represents the first in a series of interventional devices that are being developed by the firm.
Stereotaxis seeks to make the catheter commercially available for robotic electrophysiology practices in Europe upon receipt of CE mark, which could be before the end of the year.
Separately, the company is also working on the submission of an application to the US Food and Drug Administration (FDA) to begin a prospective investigational device exemption (IDE) trial in the country.
